Clinical Trial Update: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SMART) is assessing sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Bladder
• Adenocarcinoma of the Urinary Tract
• Renal Medullary Carcinoma
• Small Cell Carcinoma of the Bladder
• Small Cell Carcinoma of the Urinary Tract
• Squamous Cell Carcinoma of the Bladder
• Squamous Cell Carcinoma of the Penis
• Squamous Cell Carcinoma of the Urinary Tract

Drugs mentioned

• Atezolizumab (atezolizumab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract | Phase 2 | Status: RECRUITING